Gilead's $1,000-a-pill hepatitis C drug may make financial sense for prisons
October 20, 2014 at 17:10 PM EDT
Pricey new hepatitis C drugs, such as Gilead Sciences Inc.'s Sovaldi, may make financial sense to give to give to prisoners, one of the main groups infected with the liver-damaging virus, according to a team of Stanford University researchers...